Site Registration
Registration benefits include:
- Access to CME/CE programs
- Free subscription to Current Medical Evidence
- Reminders of new CME/CE activities
About This Section
Access a regularly updated listing of late-stage clinical trials of high relevance to clinicians who provide care to patients who have or are at risk for osteoporosis. Featured in the most recent update are studies on postmenopausal osteoporosis, secondary osteoporosis, osteoporosis in men, hip and vertebral fracture prevention, and therapeutic agents such as bisphosphonates, calcitonin, denosumab, estrogen, odanacatib, parathyroid hormone analogs, estrogen receptor agonists/antagonists, and other drugs in development.
Bisphosphonates
Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy
Condition: Osteoporosis
Interventions: Drug: Actonel®; Drug: amg 162
Sponsor: Amgen
Recruiting - verified September 2010
Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-Walking Children With Cerebral Palsy
Conditions: Osteoporosis; Cerebral Palsy
Interventions: Drug: FOSAMAX; Other: PLACEBO
Sponsor: Centre Hospitalier Universitaire de Nice
Not yet recruiting - verified January 2009
A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)
Condition: Osteoporosis
Intervention: Drug: Comparator: alendronate sodium (+) cholecalciferol
Sponsor: Merck
Active, not recruiting - verified August 2010
Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
Condition: Osteoporosis
Interventions: Drug: Denosumab; Drug: Placebo; Drug: Alendronate sodium hydrate
Sponsor: Daiichi Sankyo Co., Ltd.
Active, not recruiting - verified June 2009
Denosumab Adherence Preference Satisfaction Study
Condition: Osteoporosis
Interventions: Drug: denosumab; Drug: alendronate
Sponsor: Amgen
Active, not recruiting - verified June 2010
A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss
Condition: Osteoporosis
Intervention: Drug: MK0217/Duration of Treatment : 12 Months
Sponsor: Merck
Completed - verified November 2009
Osteoporosis Prevention With Low Dose Alendronate
Condition: Osteopenia
Interventions: Drug: alendronate; Dietary Supplement: Calcium/Vitamin D; Drug: placebo
Sponsor: University Hospital of Mont-Godinne
Enrolling by invitation - verified February 2009
Secondary Prevention of Osteoporosis
Condition: Osteoporosis
Interventions: Drug: alendronate with cholecalciferol; Drug: calcium carbonate with cholecalciferol; Behavioral: Falls prevention measures
Sponsors: National Institute on Aging (NIA); Merck; GlaxoSmithKline
Completed - verified August 2008
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Post Menopausal Women With Osteoporosis
Condition: Osteoporosis
Interventions: Drug: Zoledronic acid; Drug: Alendronate
Sponsor: Novartis
Completed - verified May 2009
Upper GI Handling of Branded vs. Generic Alendronate
Condition: Osteoporosis
Interventions: Drug: MK0217, alendronate sodium / Duration of Treatment: 1 Month; Drug: Comparator: Alendronate-Teva / Duration of Treatment: 1 Month
Sponsor: Merck
Completed - verified November 2006
A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: MK0217, alendronate sodium / Duration of Treatment : 2 Years; Drug: Comparator : calcium carbonate /Duration of Treatment : 2 Years
Sponsor: Merck
Completed - verified January 2009
FLEX - Long-term Extension of FIT (Fracture Intervention Trial)
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: MK0217, alendronate sodium / Duration of Treatment : 5 Years; Drug: Comparator : placebo (unspecified) /Duration of Treatment : 5 Years
Sponsor: Merck
Completed - verified November 2009
Fosamax for Childhood Cancer Survivors
Condition: Osteoporosis
Interventions: Drug: Alendronate; Drug: Placebo
Sponsor: Chinese University of Hong Kong
Recruiting - verified May 2008
A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: MK0217, /Duration of Treatment : 12 Months; Drug: Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months
Sponsor: Merck
Completed - verified September 2008
Study of Transitioning From Alendronate to Denosumab
Condition: Postmenopausal Osteoporosis
Interventions: Drug: alendronate; Drug: Denosumab (AMG 162)
Sponsor: Amgen
Completed - verified July 2010
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial CAN-NCIC-MA27
Conditions: Breast Cancer; Osteoporosis
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: cholecalciferol; Drug: alendronate sodium; Drug: calcium gluconate; Drug: risedronate sodium; Other: laboratory biomarker analysis; Procedure: dual x-ray absorptometry
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Southwest Oncology Group
Active, not recruiting - verified May 2010
The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.
Condition: Osteoporosis
Intervention: Drug: Alendronate
Sponsors: McGill University Health Center; Merck Frosst Canada Ltd.
Recruiting - verified January 2006
Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate
Condition: Osteoporosis
Interventions: Drug: Ibandronate; Drug: Alendronate
Sponsor: GlaxoSmithKline
Completed - verified July 2009
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
Conditions: Osteoporosis; Osteopenia
Interventions: Drug: Alendronate; Drug: Denosumab
Sponsor: Amgen
Completed - verified June 2010
Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )
Condition: Osteoporosis
Intervention: Drug: Alendronate
Sponsors: Canadian Urology Research Consortium; Abbott; Merck Frosst Canada Ltd.
Terminated - verified August 2009
Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)
Condition: Prostatic Neoplasms
Intervention: Drug: Alendronate
Sponsors: University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified June 2010
Network Osteoporosis Study
Conditions: Osteopenia; Osteoporosis
Intervention: Drug: alendronate sodium
Sponsors: Glaser Pediatric Research Network; Elizabeth Glaser Pediatric AIDS Foundation
Active, not recruiting - verified September 2005
Bone Effects of Teriparatide Following Alendronate
Condition: Osteoporosis
Intervention: Drug: teriparatide
Sponsor: Eli Lilly and Company
Completed - verified January 2007
Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
Conditions: Rheumatoid Arthritis; Polymyalgia Rheumatica; Giant Cell Arteritis; Polymyositis; Wegener’s Granulomatosis
Intervention: Drug: Alendronate versus alfacalcidol (1-alpha OH vitamin D)
Sponsors: UMC Utrecht; Dutch Health Care Insurance Board
Completed - verified March 2000
Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients
Condition: Osteoporosis
Interventions: Procedure: bone densitometry (DEXA); Drug: alendronate or risedronate
Sponsors: University of Alberta; Alberta Heritage Foundation for Medical Research
Active, not recruiting - verified May 2008
Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment
Condition: Breast Cancer
Intervention: Drug: Alendronate sodium
Sponsors: Barwon Health; AstraZeneca
Active, not recruiting - verified June 2010
Efficacy of Alendronate Versus Placebo in the Treatment of HIV-Associated Osteoporosis (ANRS120)
Conditions: Osteoporosis; HIV Infections
Intervention: Drug: Alendronate
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Completed - verified June 2009
Alendronate Osteoporosis Study
Condition: Glucocorticoid-Associated Osteopenia and Osteoporosis
Intervention: Drug: Alendronate
Sponsors: Children's Hospital Boston; Glaser Pediatric Research Network; Elizabeth Glaser Pediatric AIDS Foundation
Active, not recruiting - verified January 2006
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
Condition: Osteoporosis
Intervention: Drug: Zoledronic Acid
Sponsor: Novartis
Completed - verified September 2007
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
Condition: Osteoporosis
Intervention: Drug: zoledronic acid
Sponsor: Novartis
Completed - verified June 2006
A Study to Evaluate the Safety and Tolerability of MK0217 in Women
Condition: Postmenopausal Osteoporosis
Interventions: Drug: MK0217, alendronate sodium/Duration of Treatment: 6 months; Drug: Comparator: placebo / Duration of Treatment: 6 months
Sponsor: Merck
Completed - verified January 2010
A Study to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: MK0217, alendronate sodium/Duration of Intervention: 12 mo; Drug: Comparator: risedronate / Duration of Intervention: 12 mo
Sponsor: Merck
Completed - verified January 2010
A Study to Evaluate and Compare the Effects of Two Approved Drugs in Women With Postmenopausal Osteoporosis
Condition: Postmenopausal Osteoporosis
Interventions: Drug: MK0217, alendronate sodium/Duration of Treatment: 12 mo; Drug: Comparator: risedronate/Duration of Treatment: 12 mo
Sponsor: Merck
Completed - verified January 2010
A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis
Conditions: Osteoporosis; Vitamin D Deficiency
Intervention: Drug: MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks
Sponsor: Merck
Completed - verified January 2010
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis
Conditions: Osteoporosis; Vitamin D Deficiency
Intervention: Drug: MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks
Sponsor: Merck
Completed - verified January 2010
Study of Investigational Drug in Osteoporosis
Condition: Postmenopausal Osteoporosis
Interventions: Drug: MK0217, alendronate sodium/Duration of Treatment: 3 months; Drug: Comparator: placebo / Duration of Treatment: 3 months
Sponsor: Merck
Completed - verified January 2010
Vitamin K and Bone Turnover in Postmenopausal Women
Condition: Osteoporosis
Interventions: Drug: phylloquinone (K1); Drug: menatetranone (MK4)
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eisai Limited
Completed - verified March 2010
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
Condition: Osteoporosis
Interventions: Drug: Teriparatide; Drug: Alendronate Sodium; Drug: Placebo; Drug: Placebo
Sponsor: Eli Lilly and Company
Completed - verified February 2009
Prevention of Osteoporosis in Men With Prostate Cancer
Conditions: Prostate Cancer; Osteoporosis; Hypogonadism
Intervention: Drug: alendronate
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 2010
Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis
Conditions: Osteopenia; Osteoporosis
Interventions: Drug: Alendronate; Drug: Estrogen/progestin therapy
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Terminated - verified February 2004
Effects of Parathyroid Hormone in Men With Osteoporosis
Condition: Osteoporosis
Interventions: Drug: Parathyroid hormone; Drug: Alendronate
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed - verified February 2008
Osteoporosis Prevention After Heart Transplant
Conditions: Osteoporosis; Cardiac Transplantation
Interventions: Drug: Alendronate; Drug: Calcitriol
Sponsors: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Merck
Completed - verified February 2004
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
Condition: Postmenopausal Osteoporosis
Interventions: Drug: Ibandronate; Drug: Denosumab
Sponsor: Amgen
Recruiting - verified August 2010
Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
Condition: Hematological Malignancies
Interventions: Drug: Ibandronate; Drug: Vitamin Supplements
Sponsors: M.D. Anderson Cancer Center; Roche Pharma AG
Recruiting - verified March 2010
PTH & Ibandronate Combination Study (PICS)
Condition: Osteoporosis
Interventions: Drug: PTH(1-84); Drug: Ibandronate
Sponsor: University of California, San Francisco
Active, not recruiting - verified August 2009
BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.
Condition: Osteoporosis
Interventions: Drug: ibandronate [Bonviva/Boniva]; Drug: Placebo
Sponsor: Hoffmann-La Roche
Completed - verified August 2010
Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis
Condition: Primary Osteoporosis
Interventions: Drug: ibandronic acid 0.5mg; Drug: RIS placebo; Drug: 1.0mg ibandronic acid; Drug: ibandronic acid placebo; Drug: 2.5mg RIS; Dietary Supplement: Calcium and Vitamine D3
Sponsor: Chugai Pharmaceutical
Active, not recruiting - verified February 2010
The Effect Of Oral Ibandronate In Male Osteoporosis
Condition: Male Osteoporosis
Interventions: Drug: Ibandronate; Drug: placebo
Sponsors: Hoffmann-La Roche; GlaxoSmithKline
Completed - verified November 2009
Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate
Condition: Osteoporosis
Interventions: Drug: Ibandronate; Drug: Alendronate
Sponsor: GlaxoSmithKline
Completed - verified July 2009
Study in Elderly Patients With Early Breast Cancer (ICE)
Condition: Breast Cancer
Interventions: Drug: Ibandronate, Capecitabine; Drug: Ibandronate
Sponsors: German Breast Group; Hoffmann-La Roche; AstraZeneca
Recruiting - verified May 2008
Study of Investigational Drug in Osteoporosis
Condition: Postmenopausal Osteoporosis
Interventions: Drug: MK0217, alendronate sodium/Duration of Treatment: 3 months; Drug: Comparator: placebo / Duration of Treatment: 3 months
Sponsor: Merck
Completed - verified January 2010
MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
Condition: Post-Menopausal Osteoporosis
Interventions: Drug: ibandronate [Bonviva/Boniva]; Drug: ibandronate [Bonviva/Boniva]; Drug: ibandronate [Bonviva/Boniva]; Drug: ibandronate [Bonviva/Boniva]
Sponsor: Hoffmann-La Roche
Completed - verified May 2009
DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
Condition: Post-Menopausal Osteoporosis
Interventions: Drug: ibandronate [Bonviva/Boniva]; Drug: ibandronate [Bonviva/Boniva]; Drug: ibandronate [Bonviva/Boniva]
Sponsor: Hoffmann-La Roche
Completed - verified May 2009
Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy
Condition: Osteoporosis
Interventions: Drug: Actonel®; Drug: amg 162
Sponsor: Amgen
Recruiting - verified September 2010
Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer
Conditions: Breast Cancer; Menopause; Osteopenia
Interventions: Drug: Risedronate; Drug: Placebo
Sponsor: Hospices Civils de Lyon
Recruiting - verified November 2009
Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis
Condition: Male Osteoporosis
Interventions: Drug: Placebo tablet; Drug: Risedronate
Sponsors: Warner Chilcott; Sanofi-Aventis
Completed - verified March 2010
Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
Condition: Postmenopausal Osteoporosis
Intervention: Drug: risedronate
Sponsors: Warner Chilcott; Sanofi-Aventis
Completed - verified March 2010
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
Condition: Postmenopausal Osteoporosis
Interventions: Drug: risedronate; Drug: risedronate; Drug: risedronate
Sponsor: Procter and Gamble
Active, not recruiting - verified July 2009
Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis
Condition: Osteoporosis
Interventions: Drug: Teriparatide; Drug: Risedronate
Sponsor: Eli Lilly and Company
Active, not recruiting - verified January 2010
A Study of Actonel for the Prevention of Bone Loss
Conditions: Leukemia; Lymphoma
Interventions: Drug: Actonel (Risedronate); Dietary Supplement: Calcium; Dietary Supplement: Vitamin D
Sponsors: M.D. Anderson Cancer Center; Procter and Gamble
Recruiting - verified March 2010
Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis
Condition: Primary Osteoporosis
Interventions: Drug: ibandronic acid 0.5mg; Drug: RIS placebo; Drug: 1.0mg ibandronic acid; Drug: ibandronic acid placebo; Drug: 2.5mg RIS; Dietary Supplement: Calcium and Vitamine D3
Sponsor: Chugai Pharmaceutical
Active, not recruiting - verified February 2010
Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: risedronate; Drug: risedronate; Drug: Control
Sponsors: CMX Research; Sanofi-Aventis
Active, not recruiting - verified February 2008
Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
Condition: Osteoporosis
Intervention: Drug: Parathyroid Hormone (PTH)
Sponsor: Nycomed
Recruiting - verified August 2010
Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
Condition: Osteoporosis Postmenopausal
Intervention: Drug: Risedronate (HMR4003)
Sponsors: Sanofi-Aventis; Procter and Gamble
Completed - verified December 2009
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial CAN-NCIC-MA27
Conditions: Breast Cancer; Osteoporosis
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: cholecalciferol; Drug: alendronate sodium; Drug: calcium gluconate; Drug: risedronate sodium; Other: laboratory biomarker analysis; Procedure: dual x-ray absorptometry
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Southwest Oncology Group
Active, not recruiting - verified May 2010
Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
Condition: Osteoporosis, Postmenopausal
Intervention: Drug: risedronate (HMR4003)
Sponsors: Sanofi-Aventis; Procter and Gamble
Completed - verified December 2009
Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis
Conditions: Osteoporosis, Postmenopausal; Back Pain; Spinal Fracture
Interventions: Drug: teriparatide; Drug: risedronate; Drug: placebo; Drug: placebo
Sponsor: Eli Lilly and Company
Completed - verified August 2010
Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS
Conditions: Breast Cancer; Osteoporosis
Interventions: Drug: risedronate sodium; Other: laboratory biomarker analysis
Sponsor: International Breast Cancer Study Group
Recruiting - verified May 2007
Risedronate in Osteopenic Postmenopausal Women
Condition: Osteoporosis
Interventions: Drug: risedronate; Drug: risedronate placebo
Sponsors: Sanofi-Aventis; Procter and Gamble
Completed - verified December 2009
IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)
Condition: Osteoporosis
Intervention: Drug: risedronate
Sponsors: Sanofi-Aventis; Procter and Gamble
Completed - verified July 2008
A Study of Monthly Risedronate for Osteoporosis
Condition: Postmenopausal Osteoporosis
Interventions: Drug: risedronate; Drug: risedronate
Sponsors: Warner Chilcott; Sanofi-Aventis
Completed - verified July 2009
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
Condition: Metastatic Prostate Cancer
Interventions: Drug: Risedronate; Drug: Placebo
Sponsors: Hoosier Oncology Group; Sanofi-Aventis; Walther Cancer Institute
Active, not recruiting - verified December 2007
Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.
Condition: Acute Spinal Cord Injury.
Intervention: Drug: Risedronate
Sponsors: Toronto Rehabilitation Institute; Ontario Neurotrauma Foundation; St. Joseph's Healthcare Foundation; Queen Elizabeth Hospital Foundation
Completed - verified November 2007
Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury
Condition: Osteoporosis
Intervention: Drug: Risedronate
Sponsors: Toronto Rehabilitation Institute; The Physicians' Services Incorporated Foundation; St. Joseph's Healthcare
Active, not recruiting - verified July 2008
Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients
Condition: Osteoporosis
Interventions: Procedure: bone densitometry (DEXA); Drug: alendronate or risedronate
Sponsors: University of Alberta; Alberta Heritage Foundation for Medical Research
Active, not recruiting - verified May 2008
Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis
Condition: Osteoporosis
Intervention: Drug: Zoledronic Acid
Sponsor: Novartis
Completed - verified September 2007
A Study to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: MK0217, alendronate sodium/Duration of Intervention: 12 mo; Drug: Comparator: risedronate / Duration of Intervention: 12 mo
Sponsor: Merck
Completed - verified January 2010
A Study to Evaluate and Compare the Effects of Two Approved Drugs in Women With Postmenopausal Osteoporosis
Condition: Postmenopausal Osteoporosis
Interventions: Drug: MK0217, alendronate sodium/Duration of Treatment: 12 mo; Drug: Comparator: risedronate/Duration of Treatment: 12 mo
Sponsor: Merck
Completed - verified January 2010
Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Anastrozole; Drug: Risedronate Sodium
Sponsor: AstraZeneca
Completed - verified June 2008
Vitamin K and Bone Turnover in Postmenopausal Women
Condition: Osteoporosis
Interventions: Drug: phylloquinone (K1); Drug: menatetranone (MK4)
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eisai Limited
Completed - verified March 2010
Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
Conditions: Breast Cancer; Osteoporosis
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: cholecalciferol; Drug: risedronate sodium
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified May 2006
Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
Conditions: Osteoporosis; Prostate Cancer
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: cholecalciferol; Drug: conjugated estrogens; Drug: risedronate sodium
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified January 2007
Zoledronic Acid in MS-patients With Osteoporosis
Conditions: Osteoporosis; Multiple Sclerosis
Interventions: Drug: Zoledronic Acid; Drug: Placebo
Sponsor: Novartis
Not yet recruiting - verified July 2010
Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head
Condition: Avascular Necrosis of Femoral Head
Intervention: Drug: zoledronic acid (aclasta)
Sponsors: Seoul National University Bundang Hospital; Novartis Korea Ltd.
Recruiting - verified July 2010
A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years
Condition: Postmenopausal Osteoporosis
Intervention: Drug: Zoledronic acid
Sponsor: Novartis Pharmaceuticals
Recruiting - verified January 2010
Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss
Condition: Bone Loss
Interventions: Drug: zoledronic acid; Drug: placebo
Sponsors: Northwestern University; Novartis
Recruiting - verified July 2010
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Condition: Osteoporosis
Interventions: Drug: Zoledronic acid; Drug: Placebo
Sponsor: Novartis
Recruiting - verified July 2010
Zoledronate for Osteopenia in Pediatric Crohn's
Conditions: Crohn's Disease; Osteopenia; Osteoporosis
Interventions: Drug: zoledronic acid; Other: IV saline infusion
Sponsors: McGill University Health Center; Crohn's and Colitis Foundation
Completed - verified November 2008
3-year Efficacy and Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zoledronic Acid for 6 Years
Condition: Post-Menopausal Osteoporosis
Interventions: Drug: Placebo; Drug: Zoledronic acid
Sponsor: Novartis
Active, not recruiting - verified May 2010
Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
Condition: Male Osteoporosis
Interventions: Drug: Zoledronic acid; Drug: Placebo
Sponsor: Novartis
Active, not recruiting - verified December 2008
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
Condition: Osteoporosis
Interventions: Drug: Zoledronic acid placebo plus teriparatide; Drug: Zoledronic acid; Drug: Zoledronic acid plus teriparatide
Sponsor: Novartis
Active, not recruiting - verified January 2008
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Post Menopausal Women With Osteoporosis
Condition: Osteoporosis
Interventions: Drug: Zoledronic acid; Drug: Alendronate
Sponsor: Novartis
Completed - verified May 2009
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
Condition: Breast Cancer
Intervention: Drug: zoledronic acid
Sponsors: Soroka University Medical Center; Tel-Aviv Sourasky Medical Center
Recruiting - verified April 2007
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
Conditions: Non-Hodgkin's Lymphoma; Lymphoma
Interventions: Drug: Zoledronic Acid; Drug: Vitamin D; Drug: Calcium Carbonate
Sponsors: M.D. Anderson Cancer Center; Novartis
Active, not recruiting - verified July 2010
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Condition: Osteoporosis, Postmenopausal
Intervention: Drug: Zoledronic acid
Sponsor: Novartis
Recruiting - verified November 2009
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Condition: Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
Intervention: Drug: Zoledronic Acid
Sponsor: Novartis
Recruiting - verified November 2009
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
Conditions: Osteoporosis; Prostate Cancer
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: cholecalciferol; Drug: buserelin; Drug: calcium gluconate; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Drug: zoledronic acid; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified May 2009
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Condition: Prostate Cancer
Interventions: Procedure: External beam radiation; Drug: Lupron; Drug: Casodex
Sponsors: Schiffler Cancer Center; Kent E. Wallner, M.D.; Sylvester, John, M.D.
Recruiting - verified May 2008
The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
Condition: Prostate Cancer
Intervention: Drug: Zoledronic acid
Sponsor: Novartis
Completed - verified November 2009
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
Condition: Cancer Prostate
Intervention: Drug: Zoledronic acid
Sponsor: Novartis Pharmaceuticals
Completed - verified September 2010
Double-Blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)
Condition: Osteoporosis
Interventions: Drug: Zoledronic Acid; Drug: Placebo; Drug: Zoledronic acid
Sponsor: Novartis
Active, not recruiting - verified December 2007
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
Condition: Osteopenia
Interventions: Drug: Zoledronic Acid; Drug: Zoledronic acid; Drug: Zoledronic acid
Sponsor: Novartis Pharmaceuticals
Completed - verified December 2008
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
Conditions: Breast Cancer; Osteoporosis
Interventions: Drug: letrozole; Drug: zoledronic acid; Procedure: adjuvant therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Active, not recruiting - verified March 2006
Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis
Condition: Osteoporosis
Intervention: Drug: Zoledronic Acid
Sponsor: Novartis
Completed - verified September 2007
A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate
Condition: Osteoporosis
Intervention: Drug: zoledronic acid
Sponsor: Novartis
Completed - verified January 2006
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
Condition: Osteoporosis
Intervention: Drug: Zoledronic Acid
Sponsor: Novartis
Completed - verified September 2007
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
Condition: Osteoporosis
Intervention: Drug: zoledronic acid
Sponsor: Novartis
Completed - verified June 2006
Vitamin K and Bone Turnover in Postmenopausal Women
Condition: Osteoporosis
Interventions: Drug: phylloquinone (K1); Drug: menatetranone (MK4)
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eisai Limited
Completed - verified March 2010
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
Conditions: Osteoporosis; Prostate Cancer
Interventions: Dietary Supplement: cholecalciferol; Drug: calcium gluconate; Drug: zoledronic acid
Sponsors: Northwestern University; Novartis
Active, not recruiting - verified May 2010
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
Conditions: Breast Neoplasms; Osteoporosis
Intervention: Drug: Zoledronic Acid and Letrozole
Sponsor: Novartis Pharmaceuticals
Completed - verified May 2010
HORIZON-PFT: Pivotal Fracture Trial
Condition: Osteoporosis
Intervention: Drug: Zoledronic Acid
Sponsor: Novartis
Completed - verified October 2007
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
Conditions: Breast Cancer; Osteoporosis
Intervention: Drug: zoledronic acid
Sponsors: Herbert Irving Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified April 2007
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
Conditions: Osteoporosis; Hip Fracture
Intervention: Drug: Zoledronic Acid
Sponsor: Novartis
Completed - verified September 2007
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Conditions: Breast Cancer; Osteoporosis
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: cholecalciferol; Drug: calcium gluconate; Drug: zoledronic acid; Procedure: adjuvant therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Completed - verified March 2006
